74 related articles for article (PubMed ID: 8235703)
1. Prospects of T-cell immunotherapy for cancer by peptide vaccination.
Melief CJ
Semin Hematol; 1993 Jul; 30(3 Suppl 3):32-3. PubMed ID: 8235703
[No Abstract] [Full Text] [Related]
2. Quality and quantity: new strategies to improve immunotherapy of cancer.
Krueger C; Schneck JP; Oelke M
Trends Mol Med; 2004 May; 10(5):205-8. PubMed ID: 15121045
[TBL] [Abstract][Full Text] [Related]
3. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
Obermann S; Petrykowska S; Manns MP; Korangy F; Greten TF
Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719
[TBL] [Abstract][Full Text] [Related]
4. Gene marking.
Brenner MK
Gene Ther; 1996 Apr; 3(4):278-9. PubMed ID: 8732158
[No Abstract] [Full Text] [Related]
5. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
[TBL] [Abstract][Full Text] [Related]
6. T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.
Noy R; Eppel M; Haus-Cohen M; Klechevsky E; Mekler O; Michaeli Y; Denkberg G; Reiter Y
Expert Rev Anticancer Ther; 2005 Jun; 5(3):523-36. PubMed ID: 16250828
[TBL] [Abstract][Full Text] [Related]
7. [Cytotoxic T-lymphocytes and the recognition of tumor antigens--an approach to "preventive tumor vaccination?"].
Peiper M; Goedegebuure PS; Eberlein TJ; Zornig C
Zentralbl Chir; 1997; 122(3):141-8. PubMed ID: 9206906
[TBL] [Abstract][Full Text] [Related]
8. [Autologous tumor specific immunotherapy of refractory cancers with ex vivo-generated T cells stimulated by autologous tumor cell].
Toh U; Yamana H; Kido K; Mine T; Fujii T; Horiuchi H; Sasatomi T; Ishibashi N; Yutani S; Fujita H; Shirouzu K
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1566-70. PubMed ID: 14619465
[TBL] [Abstract][Full Text] [Related]
9. [Our experience with lymphocytes activated against cancer: CTL cells].
Marcellino LR; Vinciguerra M; Marcellino MV; Sessa E
G Chir; 1997 Oct; 18(10):605-7. PubMed ID: 9479972
[TBL] [Abstract][Full Text] [Related]
10. Transfer of in vitro expanded T lymphocytes after activation with dendritomas prolonged survival of mice challenged with EL4 tumor cells.
Li J; Theofanous L; Stickel S; Bouton-Verville H; Burgin KE; Jakubchak S; Wagner TE; Wei Y
Int J Oncol; 2007 Jul; 31(1):193-7. PubMed ID: 17549421
[TBL] [Abstract][Full Text] [Related]
11. Adoptive cellular immunotherapy for viral diseases.
Fujita Y; Rooney CM; Heslop HE
Bone Marrow Transplant; 2008 Jan; 41(2):193-8. PubMed ID: 17982497
[TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy.
Curti BD
Cancer Chemother Biol Response Modif; 1997; 17():316-27. PubMed ID: 9551218
[No Abstract] [Full Text] [Related]
13. Antigen choice in adoptive T-cell therapy of cancer.
Offringa R
Curr Opin Immunol; 2009 Apr; 21(2):190-9. PubMed ID: 19297140
[TBL] [Abstract][Full Text] [Related]
14. [Cancer immunotherapy: new approaches].
Blay JY; Thomachot MC; Alberti L; Bachelot T; Voorzanger-Rousselot N; Puisieux I; Odin L; Ménétrier-Caux C
Bull Cancer; 2000 Jan; 87(1):97-106. PubMed ID: 10673638
[No Abstract] [Full Text] [Related]
15. Generation of Ag-specific cytotoxic T lymphocytes by DC transfected with in vitro transcribed influenza virus matrix protein (M1) mRNA.
Osman Y; Narita M; Ayres F; Takahashi M; Alldawi L; Tatsuo F; Toba K; Hirohashi T; Aizawa Y
Cytotherapy; 2003; 5(2):161-8. PubMed ID: 12745578
[TBL] [Abstract][Full Text] [Related]
16. Targeting human tumours with antigen-specific cytotoxic T-cells.
Rickinson AB
Br J Cancer; 1999 Jul; 80 Suppl 1():51-6. PubMed ID: 10466763
[No Abstract] [Full Text] [Related]
17. [T-cell therapy in oncology. Therapeutic vaccination, allogeneic blood stem cell transplantation and adoptive T-cell transfer].
Kuball J; Derigs HG; Wölfel T
Dtsch Med Wochenschr; 2002 Apr; 127(14):755-62. PubMed ID: 11935475
[No Abstract] [Full Text] [Related]
18. Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer.
Chiriva-Internati M; Weidanz JA; Yu Y; Frezza EE; Jenkins MR; Kennedy RC; Cobos E; Kast WM
J Immunother; 2008 Oct; 31(8):693-703. PubMed ID: 18779750
[TBL] [Abstract][Full Text] [Related]
19. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors.
Cesano A; Visonneau S; Jeglum KA; Owen J; Wilkinson K; Carner K; Reese L; Santoli D
Cancer Res; 1996 Jul; 56(13):3021-9. PubMed ID: 8674057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
